Royal Medical Center Tirzepatide Review: Quote, Included Care and Pharmacy

Royal Medical Center’s current injection page names both tirzepatide and semaglutide and advertises a starting price of $67 per month. That mixed-product figure does not establish a tirzepatide-specific price, dose tier or whole-term charge. The page offers one-, two- and three-month programs; a personal prescription and invoice were not selected.³

Get a medication-specific quote

The useful comparison is the prescribed medication and supplied period, not the lowest number beside a GLP-1 heading. Ask which drug, formulation and quantity the quote covers, the amount collected now and the total commitment. A three-month program description alone does not establish whether payment is collected upfront or in installments.³

The weight-loss page reports an inclusive program covering medication, supplies and injections, physician consultations and follow-ups, and lab monitoring and adjustments. It also describes an evaluation, lab testing and ongoing monitoring. These are published program inclusions; confirm the services and any additional laboratory requirements for the actual plan rather than assuming every possible test is covered.⁴

Renewal, cancellation and refunds

The product and weight-loss pages do not establish a renewal-processing date, advance cancellation deadline or entitlement to an unused-term refund. That is a limit of these two pages, not evidence that no policy exists anywhere. Request the applicable payment and prescription agreement before authorizing a charge.^3,4

Ask whether the selected program renews automatically, when any next payment is processed and how to stop it. Separately ask when an existing prescription becomes noncancelable, whether clinician nonapproval changes the amount owed and what happens to unused payments. Stopping a future payment does not by itself reverse medication already prepared or dispensed.

The RyzeRx review contrasts strength-labeled injectable options with separate multi-month kits. That distinction helps when comparing Royal’s mixed-medication starting headline: establish the actual medication, supplied quantity and total before treating a starting figure as a monthly rate.⁵

Pharmacy and individual eligibility

Both pages identify Belmar Pharma Solutions in the footer as the dispensing pharmacy. This is Royal Medical Center’s reported attribution, not an independent check of credentials or proof of the facility assigned to an individual order. Obtain the actual dispenser’s legal name and contact details, formulation and state-service confirmation.^3,4

The product page describes provider-directed injectable treatment and notes that actual medication and packaging can differ from website images. Its broad program description cannot establish personal eligibility, a particular prescription or a guaranteed result. The prescriber should explain the proposed treatment and its risks.³

Evidence and comparisons

Compounded tirzepatide is not an FDA-approved finished drug. Our compounding legal-status guide explains the distinction. Discuss Zepbound side effects, gallbladder risk and the thyroid warning with the prescriber. SURMOUNT-1 and SURMOUNT-5 studied specific products and protocols, not Royal Medical Center’s service or every compounded preparation.^1,2 See the tirzepatide evidence guide for clinical context.

For alternative care arrangements, read the Rebody Health review and Ondra Health review. Compare written medication-specific totals, included monitoring and prescription-finality terms in the provider comparison.